PMID- 17430687
OWN - NLM
STAT- MEDLINE
DCOM- 20070628
LR  - 20221207
IS  - 1523-3790 (Print)
IS  - 1523-3790 (Linking)
VI  - 9
IP  - 3
DP  - 2007 May
TI  - Pancreatic cancer: an update.
PG  - 170-6
AB  - Pancreatic cancer is refractory to most chemotherapy. For many years, the only 
      active agent for this disease was gemcitabine, which has very modest activity. 
      Two new regimens, gemcitabine plus erlotinib and gemcitabine plus capecitabine, 
      have recently demonstrated statistically significant survival improvements 
      compared with single-agent gemcitabine. Several key negative studies have also 
      been reported recently. This review discusses recent trials that have changed the 
      standard of care for patients with advanced pancreatic cancer.
FAU - Kindler, Hedy Lee
AU  - Kindler HL
AD  - Section of Hematology/Oncology, University of Chicago, MC 2115, Chicago, IL 
      60637-1470, USA. hkindler@medicine.bsd.uchicago.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Oncol Rep
JT  - Current oncology reports
JID - 100888967
RN  - 0 (Quinazolines)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - U3P01618RT (Fluorouracil)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Capecitabine
MH  - Clinical Trials, Phase III as Topic
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Erlotinib Hydrochloride
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Humans
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Quinazolines/administration & dosage
MH  - Gemcitabine
RF  - 35
EDAT- 2007/04/14 09:00
MHDA- 2007/06/29 09:00
CRDT- 2007/04/14 09:00
PHST- 2007/04/14 09:00 [pubmed]
PHST- 2007/06/29 09:00 [medline]
PHST- 2007/04/14 09:00 [entrez]
AID - 10.1007/s11912-007-0018-z [doi]
PST - ppublish
SO  - Curr Oncol Rep. 2007 May;9(3):170-6. doi: 10.1007/s11912-007-0018-z.